The translation of accelerated bench research into clinical practice remains a significant and unsolved challenge.
The existing structure of clinical trials and regulatory pathways may become a major bottleneck as AI-driven discovery speeds up.
Ensuring that the massive datasets generated are useful for creating scientific knowledge and not just 'stamp collecting' was an early concern, now being addressed by LLMs.
Opportunities Identified
Using AI to transform biology from a descriptive, discovery-based science into a predictive, engineering-based one.
Developing a 'virtual cell' to accurately predict drug efficacy and off-target effects, de-risking clinical trials.
Digitally designing novel therapeutic proteins and antibodies with models like ESMFold, dramatically shortening discovery timelines.
Empowering the global scientific community by providing open-source access to state-of-the-art biological models and tools.